Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Novel OSBPL7-targeting compounds show therapeutic efficacy in models of renal disease

Sep. 22, 2021

IP6K regulates circulating phosphate and intracellular ATP in mammals

Sep. 20, 2021

Combined inhibition of RIPK1 and ferroptosis as potential therapeutic strategy for AKI

Sep. 13, 2021

Opaganib significantly decreases kidney fibrosis in in vivo model

Sep. 8, 2021

4-PBA and TUDCA reduce symptoms in murine model of Alport syndrome

Sep. 7, 2021

Vertex Pharmaceuticals presents new apolipoprotein L1 inhibitors

Aug. 26, 2021

Serodus initiates phase II/III study of SER-150 in diabetic kidney disease

Aug. 25, 2021

First patient enrolled in trial on sirolimus drug-eluting balloon for erectile dysfunction

Aug. 19, 2021

RemeGen completes phase II study of telitacicept in IgAN

Aug. 12, 2021

Goldfinch Bio initiates dosing in extension study of GFB-887 for patients with FSGS

Aug. 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.